Phase Ib/II Study: Low Dose Cyclophosphamide with Axatilimab and Retifanlimab in Metastatic TNBC

M.D. Anderson Cancer Center is evaluating the optimal dosing of low dose oral cyclophosphamide in combination with axatilimab (a CSF1R-directed mAb) and standard-dose retifanlimab (a PD-1 mAb) to treat patients with recurrent unresectable or metastatic triple negative breast cancer. Participants will maintain a medication diary of cyclophosphamide doses throughout the treatment course.